Pli­ant’s chron­ic liv­er dis­ease drug has con­sis­tent safe­ty across dose ranges, PhII da­ta show

Last year
R&D

Am­gen en­ters weight loss mar­ket with drug that shows 14.5% weight re­duc­tion

Last year
R&D

Up­dat­ed: No­vo Hold­ings pays $16.5B to take Catal­ent pri­vate — and sells three man­u­fac­tur­ing sites to No­vo Nordisk

Last year
Deals
Manufacturing

4D Mol­e­c­u­lar Ther­a­peu­tic­s' gene ther­a­py cuts Eylea use in wet AMD pa­tients, biotech di­vulges plans for piv­otal ...

Last year
R&D
Cell/Gene Tx

End of Aduhelm’s road; Janet Wood­cock ex­it in­ter­view; Stu­art Schreiber's $500M ex­per­i­ment; Ver­tex's pain ...

Last year
Weekly

Draft 340B re­forms in­clude user fees, clar­i­ty around con­tract phar­ma­cies

Last year
Pharma
FDA+

Abec­ma sales dis­ap­point again as BC­MA com­pe­ti­tion ramps up, FDA ad­comm looms

Last year
Pharma
Cell/Gene Tx

Hik­ma to pay $115M in cash, $35M in do­na­tions to set­tle opi­oid claims

Last year
Pharma
Law

Re­al Hu­mi­ra com­pe­ti­tion may not ar­rive un­til 2026, Ab­b­Vie ex­ecs tell in­vestors

Last year
R&D
Pharma

For­mer FDA com­mis­sion­ers urge SCO­TUS to pre­serve agency’s reg­u­la­tions of abor­tion pill

Last year
Pharma
FDA+

Rick Gon­za­lez lays out plan for in­ter­nal can­di­date to take over as Ab­b­Vie's CEO

Last year
People
Pharma

Biotech job mar­ket bot­toms out, hint­ing at po­ten­tial come­back, ac­cord­ing to Jef­feries

Last year
People

ARCH, one of life sci­ences' pre­mier in­vestors, eyes $3B for 13th fund

Last year
Financing
Startups

Re­gen­eron aims to stop mus­cle loss with com­bi­na­tion treat­ment ap­proach in obe­si­ty

Last year
R&D
Pharma

Hutchmed's li­cens­ing deal, worth up to $227M; Tyra's $200 PIPE

Last year
News Briefing

Un­like Mer­ck, Bris­tol My­ers to fo­cus on bolt-ons af­ter M&A spree

Last year
Deals
Pharma

No­var­tis ends li­cense agree­ment for can­cer drug with Al­lar­i­ty Ther­a­peu­tics for lack of pay­ment

Last year
Deals

Ivan Che­ung's post-Ei­sai life takes hold at Next­Point Ther­a­peu­tics; Sanofi, Take­da an­nounce CFO ex­its

Last year
People
Peer Review

Al­to Neu­ro­science and Fractyl Health add to biotech IPO mo­men­tum in Fri­day dou­ble­head­er

Last year
Financing
Startups

Take­da says farewell to CFO, suite of clin­i­cal-stage pro­grams in Q3 up­date

Last year
R&D
Pharma

Pub­li­cis Health set­tles opi­oid law­suit

Last year
Pharma
Marketing

Ex­clu­sive: Col­umn Group rais­es a new $400M+ fund and R&D hub for sin­gle-as­set bi­o­log­ics com­pa­nies

Last year
Financing
Startups

Mer­ck high­lights sub­cu­ta­neous de­mand even as Keytru­da sales soar

Last year
Pharma

Just how low did the gov­ern­ment go with first IRA of­fers? Phar­ma’s not telling

Last year
Pharma
First page Previous page 207208209210211212213 Next page Last page
A service from the Financial Times